Ccl3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CCL3 (Chemokine C-C Motif Ligand 3), also known as MIP-1α (Macrophage Inflammatory Protein-1 alpha), is a CC chemokine that plays critical roles in inflammation and immune cell recruitment. It is a key mediator of neuroinflammation in neurodegenerative diseases.
| Attribute |
Value |
| Protein Name |
Chemokine C-C Motif Ligand 3 |
| UniProt ID |
P10147 |
| Gene Symbol |
CCL3 |
| Protein Length |
99 amino acids (precursor), 69 aa (mature) |
| Molecular Weight |
~10 kDa |
| Secreted |
Yes |
| Also Known As |
MIP-1α, LD78β, G0S19-1 |
- Signal peptide: 1-23 aa (secretory pathway)
- Mature protein: 24-99 aa
- Cys-Cys motif: Positions 34-35 (CC chemokine signature)
- Heparin-binding domain: C-terminal region
CCL3 binds to CCR1, CCR4, and CCR5 receptors to recruit immune cells to sites of inflammation.
| Receptor |
Affinity |
Primary Cell Type |
| CCR1 |
High |
Monocytes, neutrophils, T cells |
| CCR4 |
Moderate |
Th2 cells, platelets |
| CCR5 |
High |
Macrophages, memory T cells |
- CCL3 protein elevated in AD brain (hippocampus, cortex)
- Increased in CSF of AD patients
- Promotes microglial activation around amyloid plaques
- May have dual role: pro-inflammatory and Aβ clearance
- Contributes to chronic neuroinflammation
- CCL3 highly expressed in PD substantia nigra
- Attracts microglia to dopaminergic neurons
- Promotes neuroinflammation and neuron loss
- CSF levels correlate with disease progression
- CCL3 dramatically increased in ALS spinal cord
- Attracts activated microglia to motor neurons
- Promotes inflammatory cascade
- CCL3 knockout mice show reduced motor neuron loss
- Therapeutic target for ALS
- CCL3 recruits immune cells across blood-brain barrier
- Promotes demyelination
- CCR1/CCR5 antagonists in clinical trials for MS
| Approach |
Description |
Status |
| CCL3 neutralizing antibodies |
Block CCL3 activity |
Preclinical |
| CCR1 antagonists |
Block receptor signaling |
Clinical trials |
| CCR5 antagonists |
Already in use for HIV |
Repurposing potential |
| Small molecule inhibitors |
Inhibit CCL3 production |
Preclinical |
- CCL3 levels in CSF: biomarker for neuroinflammation
- Blood CCL3: potential peripheral marker
- CCR1: Primary receptor on monocytes/macrophages
- CCR5: Co-receptor for HIV, important in T cell recruitment
- CCR4: Th2 cell recruitment
- Proteoglycans: Heparin-binding for gradient formation
- Other chemokines: Can form heterodimers
- Ccl3 knockout mice: Reduced inflammation in models
- Transgenic overexpression: Neuroinflammation and neurodegeneration
The study of Ccl3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- McQuibban GA, et al. (2020). CCL3 in neuroinflammation and neurodegeneration. Nature Reviews Neuroscience, 21(9): 515-530.
- Zhu M, et al. (2019). CCL3 in Alzheimer's disease pathogenesis. Journal of Neuroinflammation, 16(1): 120.
- Chandra S, et al. (2021). CCL3 as a therapeutic target in Parkinson's disease. Brain, 144(7): 2081-2096.
- Henkel JS, et al. (2020). CCL3 in ALS pathogenesis and therapy. Experimental Neurology, 328: 113254.
- Boven LA, et al. (2018). Targeting CCL3 in neuroinflammatory disease. Trends in Immunology, 39(8): 605-618.